Article
Psychiatry
Juan Wang, Feng Jiang, Yulong Zhang, Robert O. Cotes, Yating Yang, Zhiwei Liu, Xiaoshuai Ning, Tingfang Liu, Yuanli Liu, Yi-lang Tang, Huanzhong Liu
Summary: Antipsychotic polypharmacy is common among recently discharged schizophrenia inpatients in China, with a higher utilization rate of second-generation antipsychotics compared to first-generation ones. Risperidone, olanzapine, and clozapine are the most commonly used antipsychotic medications. Predictors of polypharmacy include age, geographic location, duration of illness, history of hospitalizations, and behavioral symptoms during hospitalization.
ASIAN JOURNAL OF PSYCHIATRY
(2021)
Article
Multidisciplinary Sciences
Elias D. Mouchlianitis, Lucy D. Vanes, Derek K. Tracy, Anne-Katherin Fett, Daniel Joyce, Sukhi S. Shergill
Summary: Glutamatergic dysfunction is associated with treatment resistance in individuals with schizophrenia. This study used neurochemical and functional brain imaging methods to investigate glutamatergic dysfunction and reward processing in treatment-resistant and treatment-responsive schizophrenia. The results suggest that glutamatergic differences can differentiate treatment-resistant and treatment-responsive schizophrenia, which has potential diagnostic value.
SCIENTIFIC REPORTS
(2023)
Article
Psychiatry
Robert A. McCutcheon, David Taylor, Jose Rubio, Joseph Nour, Toby Pillinger, Robin M. Murray, Sameer Jauhar
Summary: This study found that discontinuation of antipsychotic medication is associated with an increased risk of relapse in schizophrenia, which is related to receptor occupancy. Although the rate of discontinuation does not appear to affect relapse, gradual discontinuation strategies may facilitate easier reinstatement of antipsychotic medication in case of symptomatic worsening.
SCHIZOPHRENIA BULLETIN
(2023)
Article
Psychiatry
Mushde Shakir, Anne E. Willems, Peter N. van Harten, Remko van Lutterveld, Diederik E. Tenback
Summary: Switching from a combination of first- and second-generation antipsychotics to monotherapy does not increase the relapse rate and may even reduce it in long-term inpatients.
SCHIZOPHRENIA RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Yuriy M. Kositsyn, Murilo S. de Abreu, Tatiana O. Kolesnikova, Alexey A. Lagunin, Vladimir V. Poroikov, Hasmik S. Harutyunyan, Konstantin B. Yenkoyan, Allan V. Kalueff
Summary: Depression and schizophrenia are common and debilitating neuropsychiatric disorders, for which current pharmacotherapies have limited efficacy and significant side effects. This highlights the need for novel drug targets. Recent advancements in translational research, research tools, and approaches have provided potential avenues for innovative drug discovery. This article provides a comprehensive overview of current treatments and outlines potential molecular targets for these disorders, while also addressing translational challenges and unanswered questions to encourage further research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Malgorzata Urban-Kowalczyk, Magdalena Kotlicka-Antczak, Dominik Strzelecki, Ewa Rudecka, Janusz Smigielski
Summary: The study found that patients with schizophrenia have higher beta-endorphin (BE) levels compared to controls, and changes in BE concentration during treatment may be related to symptom improvement and persistent negative symptoms.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Article
Psychology, Clinical
Pierluigi Selvaggi, Sameer Jauhar, Vasileia Kotoula, Fiona Pepper, Mattia Veronese, Barbara Santangelo, Fernando Zelaya, Federico E. Turkheimer, Mitul A. Mehta, Oliver D. Howes
Summary: This study found significantly lower frontal cortical blood flow in FEP patients before antipsychotic treatment. Additionally, the relative-to-global frontal cerebral blood flow measured before antipsychotic treatment may be associated with treatment response.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Psychiatry
Ching-Hua Lin, Chun-Jen Huang, Ta-Chun Lin, Hung-Yu Chan, Jiahn-Jyh Chen
Summary: This study aimed to identify factors associated with antipsychotic polypharmacy (APP), examine its impact on rehospitalization risk, and analyze temporal trends in APP use. The findings showed that the prescription rate of APP significantly increased over the study period, and it was associated with higher doses of antipsychotics, increased use of specific medications, and a higher risk of rehospitalization.
PSYCHIATRY RESEARCH
(2023)
Article
Psychiatry
Georgia Tseligkaridou, Stephan T. Egger, Tobias R. Spiller, Lena Schneller, Fritz Frauenfelder, Stefan Vetter, Erich Seifritz, Achim Burrer
Summary: This study investigates the relationship between antipsychotic class based on dopamine D2 receptor binding affinity and aggressive events perpetrated by hospitalized patients with a psychotic disorder. The results suggest that the dopamine D2 receptor affinity has a high impact on the target of aggression in patients with a psychotic disorder under antipsychotic medication.
Article
Pharmacology & Pharmacy
A. N. I. Kenar, G. A. Unal, A. Mert, A. M. Ay
Summary: The use of dual LAIA in chronic psychotic patients can effectively reduce hospitalizations and regularize medication use. This is particularly important for patients with poor social support and irregular medication use.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Shinichiro Ochi, Hiromi Tagata, Naomi Hasegawa, Norio Yasui-Furukori, Jun-ichi Iga, Hiroko Kashiwagi, Fumitoshi Kodaka, Hiroshi Komatsu, Takashi Tsuboi, Akira Tokutani, Shusuke Numata, Kayo Ichihashi, Toshiaki Onitsuka, Hiroyuki Muraoka, Hitoshi Iida, Kazutaka Ohi, Kiyokazu Atake, Taishiro Kishimoto, Hikaru Hori, Yoshikazu Takaesu, Masahiro Takeshima, Masahide Usami, Manabu Makinodan, Naoki Hashimoto, Michiko Fujimoto, Ryuji Furihata, Tatsuya Nagasawa, Hisashi Yamada, Junya Matsumoto, Kenichiro Miura, Mikio Kido, Akitoyo Hishimoto, Shu-ichi Ueno, Koichiro Watanabe, Ken Inada, Ryota Hashimoto
Summary: The study evaluated 8306 patients with schizophrenia in Japan and found that patients with TRS who were prescribed clozapine had a higher rate of antipsychotic monotherapy compared to those who were not prescribed clozapine.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2022)
Review
Neurosciences
Jung-Jin Kim, Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand
Summary: Schizophrenia treatment relies heavily on pharmacological therapy with different antipsychotics, but the effectiveness of monotherapy is limited. Therefore, antipsychotic polypharmacy is commonly used in real world practice, despite its risks and drawbacks.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2021)
Article
Clinical Neurology
Nicholas J. Ainsworth, A. Michelle Avina-Galindo, Randall F. White, Denghuang Zhan, Elizabeth C. Gregory, William G. Honer, Fidel Vila-Rodriguez
Summary: This study analyzed the impact of clozapine, anticonvulsant medication, mood state, and ECT electrode placement on outcomes in TRP. The findings suggest that ECT may be most beneficial in patients receiving clozapine and can improve negative symptoms in depressed TRP patients. Bifrontal electrode placement is effective in TRP.
Article
Psychiatry
Markku Laehteenvuo, Jurjen J. Luykx, Heidi Taipale, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Albert Batalla, Jari Tiihonen
Summary: This study compared the effects of different antipsychotic medications on the risk of developing substance use disorder (SUD) and hospital admissions in patients with schizophrenia. The results showed that clozapine and antipsychotic polytherapy were most strongly associated with a reduced risk of developing SUD and lower relapse rates.
BRITISH JOURNAL OF PSYCHIATRY
(2022)
Article
Psychology, Multidisciplinary
Gabriele Mandarelli, Felice Carabellese, Guido Di Sciascio, Roberto Catanesi
Summary: In forensic psychiatric patient populations with high social dangerousness, the use of antipsychotic polypharmacy and high-dose antipsychotics is common. Male gender, long-acting injectable antipsychotic prescription, and aggressive behavior are associated with these therapeutic regimens.
FRONTIERS IN PSYCHOLOGY
(2022)